NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

TA265; Denosumab for the treatment of bone metastases from solid tumours

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or
Consumeds	appeal)
Manufacturers/sponsors	General
Amgen (denosumab)	Allied Health Professionals Federation
,	Board of Community Health Councils in
Patient/carer groups	Wales
Afiya Trust	British National Formulary
Anthony Pilcher Bone Cancer Trust	Care Quality Commission
Black Health Agency	Commissioning Support Appraisals
Bob Champion Cancer Trust	Service
Breakthrough Breast Cancer	Department of Health, Social Services
Breast Cancer Campaign	and Public Safety for Northern Ireland
Breast Cancer Care	Healthcare Improvement Scotland
Breast Cancer UK	 Medicines and Healthcare Products
British Lung Foundation	Regulatory Agency
Cancer52	 National Association of Primary Care
Cancer Black Care	 National Pharmacy Association
Cancer Equality	NHS Alliance
Equalities National Council	NHS Commercial Medicines Unit
Everyman	NHS Confederation
Haven	Scottish Medicines Consortium
Helen Rollason Cancer Charity	
Independent Age	Comparator manufacturers
 Independent Cancer Patients Voice 	Accord Healthcare (ibandronic acid)
James Whale Fund for Kidney Cancer	Actavis UK (ibandronic acid, sodium
Kidney Cancer UK	clodronate, zoledronic acid)
Kidney Research UK	Aspire Pharma (ibandronic acid)
Macmillan Cancer Support	Bayer (sodium clodronate)
Maggie's Centres	Beacon Pharmaceuticals (sodium
Marie Curie Cancer Care	clodronate)
Muslim Council of Britain	Britannia Health Products (disodium pamidropato)
Muslim Health Network	pamidronate)Dr Reddy's Laboratories (zoledronic
Orchid Cancer Appeal	acid)
Prostate Cancer Network	Fresenius Kabi (zoledronic acid)
Prostate Cancer Support Federation	Helm AG (zoledronic acid)
Prostate Cancer UK	Hospira UK (disodium pamidronate,
Prostate Help Association	zoledronic acid)
Rarer Cancers Foundation	 Jenson Pharmaceutical (zoledronic
Roy Castle Lung Foundation	acid)
South Asian Health Foundation	Medac GmBH UK (disodium

- Specialised Healthcare Alliance
- Tenovus
- UK Lung Cancer Coalition
- Women's Health Concern

Professional groups

- Association of Anaesthetists
- Association of Cancer Physicians
- Association of Respiratory Nurse Specialists
- Association of Surgeons of Great Britain and Ireland
- British Association for Services to the Elderly
- British Association of Surgical Oncology
- British Association of Urological Nurses
- British Association of Urological Surgeons
- British Geriatrics Society
- British Institute of Musculoskeletal Medicine
- British Institute of Radiology
- British Orthopaedic Association
- British Orthopaedic Oncology Society
- British Prostate Group
- British Psychosocial Oncology Society
- British Society of Skeletal Radiologists
- British Society of Urogenital Radiology
- British Uro-Oncology Group
- Cancer Network Pharmacists Forum
- Cancer Research UK
- National Lung Cancer Forum for Nurses
- Pelican Cancer Foundation
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
 - United Kingdom Clinical Pharmacy

- pamidronate, zoledronic acid)
- Mylan UK (ibandronic acid, zoledronic acid)
- Novartis (disodium pamidronate, zoledronic acid)
- Pfizer (zoledronic acid)
- Pharmathen (ibandronic acid)
- Roche Products (sodium clodronate, ibandronic acid)
- Sandoz (ibandronic acid, zoledronic acid))
- Stragen UK (zoledronic acid)
- Stravencon (zoledronic acid)
- Strides Arcolab International (zoledronic acid)
- Sun Pharma (zoledronic acid)
- Teva (alendronic acid, ibandronic acid, disodium pamidronate, zoledronic acid)
- Wockhardt (disodium pamidronate)
- Zentiva (ibandronic acid, zoledronic acid)

Relevant research groups

- Against Breast Cancer
- Bone Cancer Research Trust
- Bone Research Society
- Breast Cancer Hope
- Breast Cancer Research Trust
- Cochrane Breast Cancer Group
- Cochrane Lung Cancer Group
- Cochrane Prostatic Diseases Urologic Cancers Group
- Health Research Authority
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
- Ovarian & Prostate Cancer Research Trust
- Pro Cancer Research Fund
- Prostate Cancer Research Centre
- Research Institute for the Care of Older People

Assessment Group

Association

 United Kingdom Oncology Nursing Society

Others

- Department of Health
- NHS England
- NHS Hastings and Rother CCG
- NHS West Hampshire CCG
- Welsh Government

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

 National Collaborating Centre for Cancer

Associated Public Health Groups

- Public Health England
- Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.